Maxim Group Issues a Buy Rating on GW Pharma

By Ryan Adsit

Maxim Group analyst Lauren Chung reiterated a Buy rating on GW Pharma (NASDAQ: GWPH) today and set a price target of $135. The company’s shares opened today at $115.82.

Chung said:

“Epilepsy remains a challenging indication to treat, with over a third of patients (>750k patients in the U.S.) who are inadequately controlled despite several antiepileptic drugs (market of >$5B) taken concurrently. GW’s lead product, Epidiolex, an orphan drug designated oral CBD (cannabidiol), showed positive results in three P3 trials for Dravet (DS) and Lennox-Gastaut syndromes (LGS).”

According to TipRanks.com, Chung is a 2-star analyst with an average return of 2.0% and a 77.8% success rate. Chung covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, VistaGen Therapeutics, and Anavex Life Sciences.

GW Pharma has an analyst consensus of Strong Buy, with a price target consensus of $135.

Based on GW Pharma’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $2.54 million and GAAP net loss of $19.27 million. In comparison, last year the company earned revenue of $3.75 million and had a GAAP net loss of $23.84 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics from proprietary cannabinoid product platform in a broad range of disease areas. The company operates through the following segments: Commercial, Sativex Research & Development, and Pipeline Research & Development. The Commercial segment distributes and sells the commercial products and promotes Sativex through collaborations with pharmaceutical companies for the currently approved indication of spasticity due to multiple sclerosis. The Sativex Research & Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research & Development segment seeks to develop cannabinoid medications other than Sativex, which are using the proprietary cannabinoid technology platform. The company was founded by Geoffrey W. Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.